ArticleApplied microbiology and biotechnology2016
A phase trial of the oral Lactobacillus casei vaccine polarizes Th2 cell immunity against transmissible gastroenteritis coronavirus infection.
Article in Applied microbiology and biotechnology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04368351 (Evaluation of the Impact of Bacteriotherapy in the Treatment of COVID-19), which is not on this map. Cited by 26 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of the Impact of Bacteriotherapy in the Treatment of COVID-19
Who cites it
26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 39 citations in OpenAlex.
- Effectiveness of probiotics on COVID-19 prevention and treatment against mild COVID-19 in outpatient care: A systematic review.Nutrition and health · 2026Pooled it
- The efficacy of probiotics on virus titres and antibody production in virus diseases: A systematic review on recent evidence for COVID-19 treatment.Clinical nutrition ESPEN · 2021Pooled it
- Assessing immunogenicity of CRISPR-NCas9 engineered strain against porcine epidemic diarrhea virus.Applied microbiology and biotechnology · 2024Article
- The extracellular polysaccharide inhibit porcine epidemic diarrhea virus with extract and gene editing Lacticaseibacillus.Microbial cell factories · 2023Article
- Probiotic therapy, African fermented foods and food-derived bioactive peptides in the management of SARS-CoV-2 cases and other viral infections.Biotechnology reports (Amsterdam, Netherlands) · 2023Review
- Effect of probiotics as an immune modulator for the management of COVID-19.Archives of microbiology · 2023Article
- The Oral Inactivated Porcine Epidemic Diarrhea Virus Presenting in the Intestine Induces Mucosal Immunity in Mice with Alginate-Chitosan Microcapsules.Animals : an open access journal from MDPI · 2023Article
- AuxotrophicVaccines · 2022Article
- Pharmacological Efficacy of Probiotics in Respiratory Viral Infections: A Comprehensive Review.Journal of personalized medicine · 2022Review
- The Probiotic Attributes and Anti-pseudorabies Virus Evaluation ofFrontiers in veterinary science · 2022Article
- Probiotics and probiotic-based vaccines: A novel approach for improving vaccine efficacy.Frontiers in medicine · 2022Review
- Strategy of Developing Oral Vaccine Candidates Against Co-infection of Porcine Diarrhea Viruses Based on aFrontiers in microbiology · 2022Article
- Porcine deltacoronavirus and its prevalence in China: a review of epidemiology, evolution, and vaccine development.Archives of virology · 2021Review
- Immunogenicity of Recombinant-DeficientVaccines · 2021Article
- The emerging role of probiotics as a mitigation strategy against coronavirus disease 2019 (COVID-19).Archives of virology · 2021Review
- Probiotic-Based Vaccines May Provide Effective Protection against COVID-19 Acute Respiratory Disease.Vaccines · 2021Review
- Probiotic lactobacilli: Can be a remediating supplement for pandemic COVID-19. A review.Journal of King Saud University. Science · 2021Review
- Modulatory Effects of Probiotics During Pathogenic Infections With Emphasis on Immune Regulation.Frontiers in immunology · 2021Review
- The immunomodulatory effects of probiotics on respiratory viral infections: A hint for COVID-19 treatment?Microbial pathogenesis · 2020Review
- RecombinantVaccines · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transmissible gastroenteritis coronavirus (TGEV) is a member of the genus Coronavirus, family Coronaviridae, order Nidovirales. TGEV is an enteropathogenic coronavirus that causes highly fatal acute diarrhoea in newborn pigs. An oral Lactobacillus casei (L. casei) vaccine against anti-transmissible gastroenteritis virus developed in our laboratory was used to study mucosal immune responses. In this L. casei vaccine, repetitive peptides expressed by L. casei (specifically the MDP and tuftsin fusion protein (MT)) were repeated 20 times and the D antigenic site of the TGEV spike (S) protein was repeated 6 times. Immunization with recombinant Lactobacillus is crucial for investigations of the effect of immunization, such as the first immunization time and dose. The first immunization is more important than the last immunization in the series. The recombinant Lactobacillus elicited specific systemic and mucosal immune responses. Recombinant L. casei had a strong potentiating effect on the cellular immunity induced by the oral L. casei vaccine. However, during TGEV infection, the systemic and local immune responses switched from Th1 to Th2-based immune responses. The systemic humoral immune response was stronger than the cellular immune response after TGEV infection. We found that the recombinant Lactobacillus stimulated IL-17 expression in both the systemic and mucosal immune responses against TGEV infection. Furthermore, the Lactobacillus vaccine stimulated an anti-TGEV infection Th17 pathway. The histopathological examination showed tremendous potential for recombinant Lactobacillus to enable rapid and effective treatment for TGEV with an intestinal tropism in piglets. The TGEV immune protection was primarily dependent on mucosal immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.